| Achieving LDL-C target levels: the role of statins. | |
MedLine Citation:
|
PMID: 11268713 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Epidemiological and clinical studies have clearly established the link between elevated low-density lipoprotein cholesterol (LDL-C) and coronary heart disease (CHD). Consequently, treatment guidelines have been developed that identify LDL-C as a causative factor for CHD and as a target for lipid-lowering therapy. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are considered the drugs of choice for lowering LDL-C in patients with hypercholesterolaemia. However, despite the proven efficacy of statins in reducing LDL-C, many patients do not achieve recommended LDL-C target levels. Surveys suggest that patients do not receive the appropriate drugs in adequate dosage to reach LDL-C target values. Success in achieving targets is lowest in patients at the highest risk, i.e. those with established CHD. The introduction of more potent HMG-CoA reductase inhibitors, or the use of higher doses of older statins, should allow more patients to achieve LDL-C target levels. |
Authors:
|
J M Lablanche |
Related Documents
:
|
10996333 - Cardiovascular risk changes after lipid lowering medications: are they predictable? 12069383 - Lipid formulation as a drug carrier for drug delivery. 24372243 - Mesoporous materials and nanocrystals for enhancing the dissolution behavior of poorly ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current medical research and opinion Volume: 16 ISSN: 0300-7995 ISO Abbreviation: Curr Med Res Opin Publication Date: 2001 |
Date Detail:
|
Created Date: 2001-03-27 Completed Date: 2001-07-12 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0351014 Medline TA: Curr Med Res Opin Country: England |
Other Details:
|
Languages: eng Pagination: 285-95 Citation Subset: IM |
Affiliation:
|
Service de Cardiologie B et Hemodynamique, Hôpital Cardiologique, 59037 Lille, France. jmlablanche@chru-lille.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
chemistry,
pharmacology,
therapeutic use* Cholesterol, LDL / blood*, drug effects* Coronary Disease / etiology*, prevention & control* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / chemistry, pharmacology, therapeutic use* Hypercholesterolemia / complications*, drug therapy* Patient Selection Risk Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The Twenty-third Annual San Antonio Breast Cancer Symposium.
Next Document: Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.